Scientific Materials :: IMV Inc. (IMV)

Immuno-Oncology 360° Conference, February 2023

Delivery Matters: Leveraging the DPX Cancer Vaccine Platform to Educate Sustained Anti-cancer Immunity and Durable Clinical Benefit

San Antony Breast Cancer Symposium (SABCS), December 2022

Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor positive (HR+) early-stage breast cancer (ESBC).

SITC, November 2022

DPX-based immune education recruits and activates unique subsets of antigen presenting cells to drive immunogenicity of peptide antigens

SITC, November 2022

Translational analysis of advanced metastatic bladder cancer patients treated with IO combination maveropepimut-S, cyclophosphamide, and pembrolizumab

SITC, November 2022

Neoadjuvant immunotherapy combining maveropepimut-S (MVP-S) with letrozole decreases Ki67 and increases Th1 immune response in hormone receptor positive (HR+) early-stage breast cancer (ESBC)

CRI-ENCI-AACR, September 2022

Cancer-associated fibroblasts as a negative predictor of response to maveropepimut-S, a novel immune educating therapy, in patients with advanced, recurrent ovarian cancer in the DeCidE1 phase 2 trial

RIVKIN - AACR VIRTUAL OVARIAN CANCER RESEARCH SEMINAR SERIES, SEPTEMBER 2022

Maveropepimut-S, a DPX-based immune-educating therapy, shows promising and durable clinical benefit in patients with recurrent ovarian cancer, a single-arm phase II trial

ESMO, SEPTEMBER 2022

VITALIZE: A Phase 2b, Open label, Multicenter, Randomized Parallel Group, Two Stage Study of maveropepimut S, pembrolizumab, with or without Intermittent Low Dose Cyclophosphamide, in r/r DLBCL

ASCO, JUNE 2022

Pembrolizumab, Maveropepimut-S, and low-dose Cyclophosphamide in advanced epithelial Ovarian cancer: Results from phase 1 and expansion cohort of PESCO trial